PDF(Pubmed)
Abstract：
The feasibility of surgery after immunotherapy for mediastinal liposarcoma remains uncertain. Besides, the case of immunotherapy for liposarcoma is still lacking. We report a case of recurrence after resection of a left mediastinal liposarcoma. After recurrence, one course of pembrolizumab plus anlotinib hydrochloride showed no tumor shrinkage, and genetic testing showed CDK4 amplification and PD-L1 TPS <1%; therefore, the plan was changed to one course of pembrolizumab plus palbociclib, but the tumor still did not shrink. Thus, second tumor resection was performed. In addition, the postoperative pathology was still well-differentiated liposarcoma. The significance of immunotherapy in liposarcoma still needs to be further explored. In the absence of surgical contraindications, secondary surgery might be feasible.
摘要：
纵隔脂肪肉瘤免疫治疗后手术的可行性仍不确定。此外,目前仍缺乏对脂肪肉瘤的免疫治疗。我们报告了一例左纵隔脂肪肉瘤切除术后复发的病例。复发后,一个疗程的pembrolizumab加盐酸安洛替尼没有显示肿瘤缩小，基因检测显示CDK4扩增和PD-L1TPS<1%；因此，该计划更改为一个疗程的pembrolizumab加palbociclib，但是肿瘤仍然没有缩小。因此，进行了第二次肿瘤切除。此外,术后病理仍为高分化脂肪肉瘤.免疫治疗在脂肪肉瘤中的意义仍需进一步探讨。在没有手术禁忌症的情况下，二次手术可能是可行的。
